These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11294510)

  • 1. P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism.
    Hadama A; Ieiri I; Morita T; Kimura M; Urae A; Irie S; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
    Ther Drug Monit; 2001 Apr; 23(2):115-8. PubMed ID: 11294510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
    He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
    Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose.
    Feng HJ; Huang SL; Wang W; Zhou HH
    Br J Clin Pharmacol; 1998 Jan; 45(1):27-9. PubMed ID: 9489590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
    Sohn DR; Kwon JT; Kim HK; Ishizaki T
    Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
    Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
    Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
    Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y
    Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans.
    Kobayashi K; Morita J; Chiba K; Wanibuchi A; Kimura M; Irie S; Urae A; Ishizaki T
    Pharmacogenetics; 2004 Aug; 14(8):549-56. PubMed ID: 15284537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics.
    Mamiya K; Hadama A; Yukawa E; Ieiri I; Otsubo K; Ninomiya H; Tashiro N; Higuchi S
    Eur J Clin Pharmacol; 2000; 55(11-12):821-5. PubMed ID: 10805060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
    Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
    Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
    Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
    Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase.
    Zhou HH
    Clin Chim Acta; 2001 Nov; 313(1-2):203-8. PubMed ID: 11694260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.
    Britzi M; Bialer M; Arcavi L; Shachbari A; Kapitulnik T; Soback S
    Ther Drug Monit; 2000 Oct; 22(5):510-6. PubMed ID: 11034254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
    Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
    J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population.
    Xie HG; Huang SL; Xu ZH; Xiao ZS; He N; Zhou HH
    Pharmacogenetics; 1997 Apr; 7(2):115-9. PubMed ID: 9170148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
    Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
    Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK; Brøsen K; Hansen MG; Gram LF
    Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
    Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
    Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.
    Ishizaki T; Chiba K; Manabe K; Koyama E; Hayashi M; Yasuda S; Horai Y; Tomono Y; Yamato C; Toyoki T
    Clin Pharmacol Ther; 1995 Aug; 58(2):155-64. PubMed ID: 7648765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
    Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
    Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation.
    Brockmöller J; Rost KL; Gross D; Schenkel A; Roots I
    Pharmacogenetics; 1995 Apr; 5(2):80-8. PubMed ID: 7663532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.